Back to mobile site

Biogen (BIIB) Misses Q4 EPS by 23c, Offers Guidance

February 13, 2024 7:00 AM EST

Biogen (NASDAQ: BIIB) reported Q4 EPS of $2.95, $0.23 worse than the analyst estimate of $3.18. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.47 billion.

GUIDANCE:

Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.64.

For earnings history and earnings-related data on Biogen (BIIB) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance

Related Entities

Earnings